Measurement of antilymphokine serum activities by the electrophoretic mobility test.

Purified human lymphocytes from peripheral blood were stimulated by Con A and the concentrated supernatants were used to induce antibodies in rabbits. These antilymphokine immune sera (ALKS) were able to inhibit the electrophoretic mobility of indicator cells, which was performed using supernatants of lymphocytes stimulated by Con A or PPD and tanned sheep red blood cells as indicator particles. If the method is standardized it is possible to compare several ALKS from different origin even in different models.

Glia cell stimulating factor (GSF): a new lymphokine. Part 2. Cellular sources and partial purification of human GSF.

Glia cell proliferation is characteristic of many inflammatory and degenerative processes in the brain, however the mechanisms underlying this response are poorly understood. We described a glia cell stimulating factor (GSF), produced by murine spleen cells, which activates DNA- and RNA synthesis of cultured glia cells. In the present series of experiments, we examined the ability of Concanavalin A (ConA)-stimulated human peripheral blood mononuclear leukocytes (PBM) and two continuous cell lines derived from human lymphocytes to spontaneously release of GSF in culture.

Induction of immunological tolerance to the penicilloyl antigenic determinant. III. Suppression of benzylpenicilloyl-specific IgE antibody formation by cleavable penicilloylated dextran.

The suppressive effect of cleavable penicilloylated dextran (BPO-DEX), whose directly bound penicilloyl groups undergo hydrolytic cleavage within 3 days under physiological conditions, on murine IgE antibody formation against the benzylpenicilloyl (BPO) determinant was investigated in BALB/c and C3H mice. Intraperitoneal administration of BPO-DEX during either primary or secondary IgE responses to BPO ascaris produced a reversible suppression of BPO-specific IgE, while not affecting carrier-specific IgE antibody formation. Suppression of longer duration, at least 10 weeks, was achieved, however, by repeated administrations of BPO-DEX.